India's COVID-19 tally climbed to 4,33,19,396 on Tuesday with 9,923 fresh cases, while the number of active cases increased to 79,313, according to Union health ministry data. The death toll climbed to 5,24,890 with 17 new fatalities, the data updated at 8 am stated.
The active cases comprise 0.18 per cent of the total infections. The national COVID-19 recovery rate was recorded at 98.61 per cent, the ministry said. An increase of 2,613 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.
The daily positivity rate was recorded at 2.55 per cent and the weekly positivity rate at 2.67 per cent, the ministry said. The number of people who have recuperated from the disease surged to 4,27,15,193, while the case fatality rate stood at 1.21 per cent, it said.
So far, 196.32 crore COVID-19 vaccine doses have been administered in the country under the nationwide inoculation drive, according to the ministry. India's COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the 1-crore mark on December 19. India's COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16.
India crossed the grim milestone of 2 crore on May 4, 3 crore on June 23 and 4 crore on January 25 this year.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.